Skip to main content

BioMarin Pharmaceutical Inc. (BMRN)

NASDAQ: BMRN · Delayed Price · USD
78.32
+0.94 (1.22%)
After-hours:Sep 20, 2021 7:47 PM EDT
77.38
-0.38 (-0.49%)
At close: Sep 20, 4:00 PM
Market Cap14.19B
Revenue (ttm)1.92B
Net Income (ttm)837.21M
Shares Out182.84M
EPS (ttm)4.40
PE Ratio17.58
Forward PE46.30
Dividendn/a
Ex-Dividend Daten/a
Volume1,072,657
Open77.26
Previous Close77.76
Day's Range76.84 - 78.69
52-Week Range71.65 - 92.57
Beta0.53
AnalystsBuy
Price Target110.83 (+43.2%)
Est. Earnings DateOct 28, 2021

About BMRN

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise ...

IndustryBiotechnology
IPO DateJul 23, 1999
CEOJean-Jacques Bienaime
Employees3,059
Stock ExchangeNASDAQ
Ticker SymbolBMRN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 23 analysts, the average rating for BMRN stock is "Buy." The 12-month stock price forecast is 110.83, which is an increase of 43.23% from the latest price.

Price Target
$110.83
(43.23% upside)
Analyst Consensus: Buy

News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioMarin Pharmaceutical Inc. - BMRN

NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN).

1 week ago - PRNewsWire

Stifel Upgrades This Pharma Stock On Prospective FDA Approval For Dwarfism Drug

Stifel has upgraded BioMarin Pharmaceutical Inc's (NASDAQ:BMRN) to Buy from Hold with a price target of $96, up from $86.  After the stock's "significant underperformance" since August 2020, analyst Pau...

1 week ago - Benzinga

BioMarin (BMRN) Phenylketonuria Gene Therapy on Clinical Hold

BioMarin's (BMRN) phase I/II study on gene therapy candidate, BMN 307, has been placed under a clinical hold by the FDA possibly on malignancy concerns.

1 week ago - Zacks Investment Research

FDA Slaps Clinical Hold on BioMarin's Gene Therapy For Genetic Metabolism Disorder

​​​​​​BioMarin Pharmaceutical Inc (NASDAQ: BMRN) faces another setback in its gene therapy development program after the FDA placed the phenylketonuria (PKU) gene therapy trial on hold. The Phase 1/2 Ph...

2 weeks ago - Benzinga

U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim...

SAN RAFAEL, Calif., Sept. 6, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S Food and Drug Administration (FDA) placed a clinical hold on the BMN 307 Phearl...

2 weeks ago - PRNewsWire

BioMarin's (BMRN) Dwarfism Drug Gets Approval in Europe

Biomarin Pharmaceutical's (BMRN) Voxzogo is the first medicine in Europe to be approved to treat achondroplasia, the most common form of dwarfism.

3 weeks ago - Zacks Investment Research

Why Is BioMarin (BMRN) Up 0.4% Since Last Earnings Report?

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?

3 weeks ago - Zacks Investment Research

Drug For Short-Limbed Dwarfism From Biomarin Wins European Approval

The European Commission (EC) has approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Voxzogo (vosoritide) once-daily injection to treat achondroplasia. The approval covers children from 2 years until ...

3 weeks ago - Benzinga

European Commission Approves BioMarin's VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from ...

SAN RAFAEL, Calif., Aug. 27, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Commission (EC) has granted marketing authorization for VOXZOGO® (vosoriti...

3 weeks ago - PRNewsWire

BioMarin to Participate in Three Upcoming Virtual Investor Conferences

SAN RAFAEL, Calif., Aug. 25, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in three upcoming virtual investor conferences.

3 weeks ago - PRNewsWire

Get Ready for a Potential Double in This Biopharmaceutical Stock in the Next 6 to 12 Months

All it will take is an FDA approval and a partial repeat of history.

Other symbols:ASND
1 month ago - The Motley Fool

BioMarin (BMRN) Beats on Q2 Earnings, Ups 2021 Guidance

BioMarin (BMRN) beats on both earnings and revenues in the second quarter of 2021.

1 month ago - Zacks Investment Research

BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to Vimizim, Naglazyme, and Palynziq produ...

1 month ago - Benzinga

BioMarin Pharmaceutical (BMRN) Tops Q2 Earnings and Revenue Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of 76.67% and 11.78%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Biomarin Pharmaceutical: Q2 Earnings Insights

Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 143.75% over the past year to $0.07, wh...

1 month ago - Benzinga

BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates

SAN RAFAEL, Calif., July 28, 2021 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2021 2020 % C...

1 month ago - PRNewsWire

BioMarin (BMRN) Upgraded to Strong Buy: Here's What You Should Know

BioMarin (BMRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 month ago - Zacks Investment Research

Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

BioMarin Shares 5-Year Data From Open-Label Trial Of Hemophilia Gene Therapy

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has announced new data from open-label Phase 1/2 trial of valoctocogene roxaparvovec, an investigational gene therapy candidate for severe hemophilia A. Data w...

1 month ago - Benzinga

BioMarin Announces Oral Presentation at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congr...

SAN RAFAEL, Calif., July 21, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today new data for valoctocogene roxaparvovec, an investigational gene therapy treatment for adult...

1 month ago - PRNewsWire

BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxap...

SAN RAFAEL, Calif., July 19, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced new data for valoctocogene roxaparvovec, an investigational gene therapy for the treatment o...

2 months ago - PRNewsWire

BioMarin (BMRN) Gets EMA Validation for Hemophilia Gene Therapy

The EMA validates BioMarin's (BMRN) marketing application for valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.

2 months ago - Zacks Investment Research

BioMarin Expects EMA's CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q'22

The European Medicines Agency (EMA) has validated BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) marketing application seeking approval for hemophilia A gene therapy, valoctocogene roxaparvovec. With toda...

2 months ago - Benzinga

European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to ...

SAN RAFAEL, Calif., July 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) validated the Company's Marketing Authorization App...

2 months ago - PRNewsWire

BioMarin to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, July 28 at 4:30pm ET

SAN RAFAEL, Calif., July 14, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a co...

2 months ago - PRNewsWire